Table 18Sensitivity analysis on cardiovascular risks for COX-2 inhibitors

Incremental cost-effectiveness ratio (£ per QALY) *
Celecoxib 200 mg + PPIEtoricoxib 60 mg + PPI
Base-case analysis
Age 55, 3 months£9,499£25,836
Age 55, 2 years£10,183£27,242
Age 65, 3 months£10,173£67,559
Age 65, 2 years£10,349£46,374
Equal stroke risks for all Cox-2s (MEDAL)
Age 55, 3 months£54,046£38,110
Age 55, 2 years£49,640£36,736
Age 65, 3 months£443,694£161,480
Age 65, 2 years£71,013£61,105
*

Compared with the next best, non-dominated option: diclofenac 100 mg + PPI for age 55 base-case analysis; Ibuprofen 1200 mg + PPI for age 55 equal stroke risks analysis; no treatment for age 65.

From: Appendix D, Details of the NSAID/COX-2 inhibitor health economic model

Cover of Osteoarthritis
Osteoarthritis: National Clinical Guideline for Care and Management in Adults.
NICE Clinical Guidelines, No. 59.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.